Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT, 3D-CRT) Internal (LDR, HDR)), Application (Prostate, Breast, Lung), End User (Hospitals) - Global Forecasts to 2026
[259 Pages Report] The global radiotherapy market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period. Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market. Additionally, the growing adoption of radiotherapy procedures for cancer treatment, increasing use of particle therapy for cancer treatment, and the rising number of conferences and symposia focusing on the advancements in radiotherapy are some of the other major factors driving the growth of this market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on the global radiotherapy market
Globally, the outbreak of COVID-19 has impacted every aspect of the medical device industry, including radiotherapy devices. From region to region, there is considerable variation in the management of radiotherapy procedures during the COVID-19 pandemic. The global cancer burden is expected to rise by 20% as a result of COVID-19. This can be attributed to the temporary postponement of various elective surgeries, as governments and authorities seek to ensure the availability of resources for COVID-19 patients. In 2020, mean weekly radiotherapy courses fell by 19.9% in April, 6.2% in May, and 11.6% in June, compared with corresponding months in 2019. A relatively greater fall was observed for attendances (29.1% in April, 31.4% in May, and 31.5% in June). Various governments have provided guidelines on elective surgeries to reduce the strain on the healthcare system, decrease disease transmission, and conserve personal protective equipment (PPE).
Though radiotherapy emergency services were available in almost all centers, the number of emergency patients visiting centers for treatment has reduced. Closed manufacturing facilities due to lockdowns have disrupted supply chains, and reduced recruitments for clinical trials further impacted the growth of the overall radiotherapy devices market in 2020.
Radiotherapy Market Dynamics
Driver: Technological advancements
Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cost, and easy-to-use radiotherapy products with improved and precise radiation dose delivery to offer increased efficiency in targeting tumors. The advancement from 2D to 3D conformal radiotherapy with real-time imaging has enabled high conformity of radiation to the target (with minimal exposure to normal tissue) and dose escalation with improved tumor control. Products that provide these benefits are expected to have a very high growth potential in a short time span, especially in mature markets where the adoption rate of technologically advanced products is high.
Considering these factors, several key market players are continuously focusing on the development, approval, and launch of technologically advanced products. For example, in 2020, Elekta (Sweden) introduced its Elekta Harmony linear accelerator, a cancer treatment system with a shorter treatment slot of up to 25% and a 30% smaller footprint. In 2020, PMB, a subsidiary of the ALCEN Group, announced the launch of FLASHKNiFE, a FLASH radiotherapy system dedicated to clinical trials.
Such technological advancements focus on improving the functionality of radiotherapy delivery systems and expanding their application areas. The growing adoption of these systems in multiple applications and settings is one of the major factors driving the growth of the radiotherapy market.
Restraint: Lack of adequate healthcare infrastructure
Radiotherapy devices are larger in size and require ample space for installation. As a result, in emerging and underdeveloped economies, the lack of adequate healthcare infrastructure due to limited healthcare expenditure is one of the major factors restraining the adoption of radiotherapy systems. Currently, only a limited number of healthcare institutions in underdeveloped and developing countries are capable of using advanced radiotherapy systems for cancer treatment. This, in turn, is limiting the number of radiotherapy procedures in spite of their high demand. The WHO recommends at least one teletherapy unit per million population. As per this recommendation, the minimum required a number of teletherapy units in India is around 1,250 units as against the presently available 545 units, marking a huge shortfall of nearly 700 units.
Opportunity: Rising healthcare expenditure across developing countries
The rapid economic development and increasing healthcare expenditure in several emerging countries, such as China, India, Brazil, and Mexico, are expected to improve access to quality healthcare in these countries. This is considered a positive indicator for the radiotherapy market. The rising incidence of cancer in these countries is resulting in a growth in the demand for various radiotherapy devices and techniques. Moreover, governments across these countries are focused on providing modern and advanced healthcare services to larger proportions of their population, as well as the improvement of reimbursement coverage. Rapid growth in per-capita healthcare expenditure and the growing public demand for affordable healthcare services are driving the growth of healthcare products (including oncology devices) across these countries. This can be evidenced by the overall increase in healthcare expenditure. For example, the healthcare expenditure of India increased from 1.2% to 2.5% of the total GDP from 2019 to 2020. Whereas, in China, healthcare expenditure has increased to 12.6% to ~USD 930 billion, as the government has raised spending in the healthcare sector amidst the COVID-19 pandemic (Source: Healthcare Asia).
Challenge: Risk of radiation exposure
One of the major challenges associated with the use of radiation therapy for cancer treatment is the risk of radiation exposure. The high radiation doses involved with therapeutic exposures have the potential to cause harm to not only the patients opting for treatment but also to the healthcare staff and people in the surrounding areas in case there is involuntary radiation exposure. This may result in various side effects, such as vomiting, diarrhea, and nausea. Similarly, exposure to a large amount of radiation doses all at once may cause radiation sickness and death.
To know about the assumptions considered for the study, download the pdf brochure
The linear accelerators segment accounted for the largest share of the external beam radiotherapy market, by product, in 2020
The EBRT products segment is further categorized into linear accelerators (LINAC), particle therapy systems, and conventional cobalt-60 teletherapy units. The Linear accelerator segment accounted for the largest market share amongst the EBRT products in 2020. A linear accelerator is the primary and most widely used treatment unit in EBRT. The LINAC segment is further characterized into conventional LINAC systems and stereotactic advanced electron/cobalt-60 LINAC systems.
LINAC systems use high-energy radiofrequency electromagnetic waves to amplify the velocity of charged subatomic particles to high energies in a linear path. These accelerators consist of a few major components—a modulator, gantry, an electron gun, an RF power source, and an accelerator guide. LINACs can be used with IMRT, IGRT, 3D conformal radiotherapy (3D-CRT), and stereotactic technology. Medical LINAC systems are the most widely used devices to deliver conventional EBRT, such as IMRT, IGRT, volumetric modulated arc therapy (VMAT), SRS, and SBRT.
The breast cancer segment, by application, to register significant growth in the Internal Beam radiotherapy market over the forecast period
The internal beam radiotherapy/brachytherapy applications market is segmented into prostate cancer, gynecological cancer, breast cancer, cervical cancer, penile cancer, and other cancers. The breast cancer segment accounted for the highest growth amongst the internal beam radiotherapy applications market in the forecast period. Brachytherapy is frequently used as a replacement for the traditional whole-breast external radiation therapy. HDR brachytherapy delivers a precise, highly concentrated radiation dose to the target tumor, with shorter treatment times and limited exposure to healthy breast tissues. Brachytherapy also helps in retaining most healthy breast tissues, thus restoring the cosmetic look of the breast. Owing to all these factors, brachytherapy has become the gold standard for the treatment of breast cancer. Early-stage breast cancer, locally advanced breast cancer with no metastasis and chest-wall breast cancer (which cannot be treated through surgery) are the major application areas for HDR brachytherapy.
Image guided radiotherapy (IGRT) segment, by procedure, accounted for the highest market share in the external beam radiotherapy market by procedures in 2020
The external beam radiotherapy segment is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT. The IGRT segment accounted for the highest share of the external beam radiotherapy market in 2020. IGRT involves the use of images taken before and during treatment, allowing radiation oncologists to adjust the position of the patient to precisely target the tumor and limit exposure to normal tissues.
Factors such as the longer treatment planning and procedural timing as well as errors due to patient positioning and lack of appropriate guidance on dose management equipment (especially in emerging countries) may pose a challenge to the growth of the IGRT market. Furthermore, image-guided radiation therapy increases the complexity associated with radiation planning and the delivery process as stringent quality assurance at every level becomes very important for effective and safe treatment.
The Asia Pacific market is expected to grow at the highest CAGR during the forecast period
The radiotherapy market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Improving healthcare infrastructure in the region, the large patient population for target diseases, and expanding presence of key market players in the region to grab elevating opportunities offered by these countries are the key factors supporting the market growth in this region.
Key Market Players
The dominant players in the global radiotherapy market are Varian Medical Systems, Inc. (US), Elekta (Sweden) Accuray Incorporated (US), Ion Beam Applications SA (Belgium), BD (US), Eckert & Ziegler (Germany), Hitachi Ltd. (Japan), ICAD, Inc. (US), IntraOp Medical, Inc. (US), IsoRay Medical, Inc. (US), Mevion Medical Systems, Inc. (US), Panacea Medical Technologies Pvt. Ltd. (India), P-cure Ltd. (Israel), ViewRay, Inc. (US), and ZEISS Group (Germany), among others.
Varian Medical Systems (US) is one of the leading players in the global radiotherapy market. Its broad portfolio of radiotherapy systems and brachytherapy products is the key factor accounting for its large share in this market. The company is focused on organic strategies such as product launches and introduced a number of new and advanced radiotherapy systems and received regulatory approvals for products in the past three years, such as the ProBeam 360 single-room proton therapy system, ProBeam 360 with multi-room configuration, Halcyon 2.0 system, and Calypso Anchored beam transponder system for LINACS, among others. It also adopted inorganic strategies such as agreements, partnerships, collaborations, and contracts to enhance its market presence.
Scope of the report
|
Report Metric |
Details |
|
Market size available for years |
2019–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD Billion) |
|
Segments covered |
Product, Application, Procedure, End User, and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
|
Companies covered |
The dominant players in the global radiotherapy market are Varian Medical Systems, Inc. (US), Elekta (Sweden) Accuray Incorporated (US), Ion Beam Applications SA (Belgium), BD (US), Eckert & Ziegler (Germany), Hitachi Ltd. (Japan), ICAD, Inc. (US), IntraOp Medical, Inc. (US), IsoRay Medical, Inc. (US), Mevion Medical Systems, Inc. (US), Panacea Medical Technologies Pvt. Ltd. (India), P-cure Ltd. (Israel), ViewRay, Inc. (US), and ZEISS Group (Germany), among others. |
This report has segmented the global radiotherapy market based on product, application, procedure, end user, and region.
Global Radiotherapy market, by Product
- External Beam Radiotherapy
- Electron-emitting High-energy Linear Accelerators
- Conventional Linear Accelerators
- Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators
- Gamma Knife
- CyberKnife
- TomoTherapy
- Conventional Cobalt-60 Teletherapy Units
- Particle Therapy Systems
- Cyclotrons
- Synchrotrons
- Synchrocyclotron
- Internal Beam Radiotherapy/Brachytherapy
- Seeds
- Afterloaders
- Applicators
- IORT Systems
- Systemic Radiotherapy
- Iobenguane (I-131)
- Samarium-153
- Rhenium-186
- Other Systemic Radiotherapy Products*
Global Radiotherapy market, by Application
- External Beam Radiotherapy
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Other Cancers
- Internal Beam Radiotherapy/Brachytherapy
- Prostate Cancer
- Gynecological Cancer
- Breast Cancer
- Cervical Cancer
- Penile Cancer
- Other Cancers
Global Radiotherapy market, by Procedure
- External Beam Radiotherapy
- Image-guided Radiotherapy
- Intensity-modulated Radiotherapy
- Stereotactic Therapy
- Particle Therapy
- 3D Conformal Radiotherapy
- Internal Beam Radiotherapy/Brachytherapy
- High-dose-rate Brachytherapy
- Low-dose-rate Brachytherapy
- Pulsed-dose-rate Brachytherapy
- Systemic Radiotherapy
- Intravenous Radiotherapy
- Oral Radiotherapy
- Instillation Radiotherapy
Global Radiotherapy market, by End User
- Hospitals
- Independent Radiotherapy Centers
Global Radiotherapy market, by Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Middle East & Africa
Recent Developments
- In November 2020, Elekta AB (Sweden) received CE mark for the Elekta Harmony linear accelerator, clearing the technology for commercial sales in Europe.
- In April 2020, Elekta AB (Sweden) launched Geneva, the first universal gynecological applicator for brachytherapy. Geneva applicator is CE-marked and has received US FDA 510(k) clearance. It is used for cervical cancer up to stage IIB.
- In June 2020, Accuray Incorporated (US) launched the CyberKnife S7 System, an innovative device combining speed, advanced precision, and real-time AI-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments.
Frequently Asked Questions (FAQ):
What is the expected addressable market value of major radiotherapy products over a 5-year period?
The global radiotherapy market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period
Which product segment is expected to garner the highest traction within the radiotherapy market?
On the basis of product, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic radiotherapy products. The external beam radiotherapy segment is expected to grow with the highest rate in the forecasted period.
What are the strategies adopted by the top market players to penetrate emerging regions?
The key growth strategies adopted by the top players in this market include product launches and approvals; agreements and partnerships; expansions; and acquisitions.
What are the major factors expected to limit the growth of the radiotherapy market?
The major challenges faced during radiotherapy procedures is the lack of clear visualization of tumors and their demarcation from normal healthy tissues and are expected to limit the market growth.
What is the adoption pattern for novel radiotherapy products across major healthcare markets?
North America accounted for the largest share of the global radiotherapy market in 2020. The rising incidence of cancer, easy accessibility and high adoption of advanced diagnostic technologies, and favorable government initiatives that are creating awareness and promoting the adoption of radiotherapy are some of the major factors driving the growth of the radiotherapy market in North America. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 33)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: RADIOTHERAPY MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 USAGE-BASED MARKET ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL RADIOTHERAPY MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 6 RADIOTHERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 7 EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 8 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)
FIGURE 9 RADIOTHERAPY MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE RADIOTHERAPY MARKET
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 RADIOTHERAPY MARKET OVERVIEW
FIGURE 11 RISING CANCER PREVALENCE ACROSS THE GLOBE TO DRIVE THE GROWTH OF THE RADIOTHERAPY MARKET
4.2 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT AND REGION
FIGURE 12 LINER ACCELERATORS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE
4.3 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 13 PROSTATE CANCER TREATMENT IS THE LARGEST APPLICATION OF INTERNAL BEAM RADIOTHERAPY IN NORTH AMERICA
4.4 GEOGRAPHIC SNAPSHOT OF THE RADIOTHERAPY MARKET
FIGURE 14 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 53)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements
5.2.1.2 Expansion of the target patient population
5.2.1.3 Increasing number of conferences and symposia focusing on spreading awareness about the benefits of radiotherapy
5.2.1.4 Growing use of particle therapy for cancer treatment
5.2.2 KEY MARKET RESTRAINTS
5.2.2.1 Lack of adequate healthcare infrastructure
5.2.2.2 Shortage of skilled oncologists/radiologists
5.2.2.3 Affordability and accessibility of treatment
5.2.2.4 Complex nature of radiotherapy
5.2.3 KEY MARKET OPPORTUNITIES
5.2.3.1 Rising healthcare expenditure across developing countries
5.2.3.2 Growing government and private investments to meet the increasing demand for cancer treatment
5.2.4 CHALLENGES
5.2.4.1 Difficulties in visualizing tumors during radiotherapy procedures
5.2.4.2 Risk of radiation exposure
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 OVERVIEW
TABLE 1 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.2 THREAT OF NEW ENTRANTS
FIGURE 16 THREAT OF NEW ENTRANTS
5.3.3 THREAT OF SUBSTITUTES
FIGURE 17 THREAT OF SUBSTITUTES
5.3.4 BARGAINING POWER OF SUPPLIERS
FIGURE 18 BARGAINING POWER OF SUPPLIERS
5.3.5 BARGAINING POWER OF BUYERS
FIGURE 19 BARGAINING POWER OF BUYERS
5.3.6 DEGREE OF COMPETITION
FIGURE 20 DEGREE OF COMPETITION
5.4 REGULATORY SCENARIO
5.4.1 US
TABLE 2 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.2 EUROPE
5.4.3 JAPAN
TABLE 3 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.4.4 EMERGING COUNTRIES
5.5 REIMBURSEMENT SCENARIO
TABLE 4 REIMBURSEMENT CODES FOR RADIOTHERAPY AND RELATED PROCEDURES
5.6 ECOSYSTEM COVERAGE
5.7 VALUE CHAIN ANALYSIS
5.8 COVID-19 IMPACT ON THE RADIOTHERAPY MARKET
5.9 PRICING ANALYSIS
5.10 PATENT ANALYSIS
5.10.1 PATENT DETAILS
FIGURE 21 PATENT ANALYSIS, JANUARY 2011–MARCH 2021
6 RADIOTHERAPY MARKET, BY PRODUCT (Page No. - 76)
6.1 INTRODUCTION
TABLE 5 RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 EXTERNAL BEAM RADIOTHERAPY PRODUCTS
TABLE 6 EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 7 EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.1 LINEAR ACCELERATORS
TABLE 8 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 9 LINEAR ACCELERATORS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.2 CONVENTIONAL LINEAR ACCELERATORS
6.2.2.1 Lower equipment and maintenance cost will drive the market for conventional LINACs
TABLE 10 CONVENTIONAL LINEAR ACCELERATORS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.3 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS
TABLE 11 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 12 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.3.1 Cyberknife
6.2.3.1.1 CyberKnife offers a precise radiation delivery method with specialized tracking and robotic correction capabilities
TABLE 13 CYBERKNIFE MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.3.2 Gamma knife
6.2.3.2.1 Gamma Knife offers promising results for brain metastasis patients
TABLE 14 GAMMA KNIFE MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.3.3 Tomotherapy
6.2.3.3.1 Continuous product development and launches adding to the growth prospects of this market segment
TABLE 15 TOMOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.4 PARTICLE THERAPY SYSTEMS
TABLE 16 PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 17 PARTICLE THERAPY SYSTEMS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.4.1 Cyclotrons
6.2.4.1.1 Leading players in the particle therapy market mainly manufacture cyclotrons
TABLE 18 CYCLOTRONS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.4.2 Synchrotrons
6.2.4.2.1 Increasing investments for the development of synchrotron facilities are contributing to market growth
TABLE 19 SYNCHROTRONS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.4.3 Synchrocyclotrons
6.2.4.3.1 High space requirements of synchrocyclotrons are limiting their widespread adoption
TABLE 20 SYNCHROCYCLOTRONS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.5 CONVENTIONAL COBALT-60 TELETHERAPY UNITS
6.2.5.1 High cost and risk of radiation exposure with cobalt-60 radio isotopes have hindered the growth of this segment
TABLE 21 CONVENTIONAL COBALT-60 TELETHERAPY UNITS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS
TABLE 22 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 23 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.1 SEEDS
6.3.1.1 Adverse side-effects associated with seeds limit their adoption
TABLE 24 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY SEEDS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.2 APPLICATORS
6.3.2.1 Manual applicators pose a high risk of radiation exposure to the patients and staff
TABLE 25 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATORS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.3 AFTERLOADERS
6.3.3.1 Modern afterloaders offer proper positioning and better control of isotopes inside the body of patients
TABLE 26 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY AFTERLOADERS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.4 IORT SYSTEMS
6.3.4.1 Growing adoption of electronic brachytherapy procedures to support the growth of this market segment
TABLE 27 IORT SYSTEMS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.4 SYSTEMIC RADIOTHERAPY
6.4.1 IOBENGUANE (I-131)
6.4.2 SAMARIUM-153
6.4.3 RHENIUM-186
6.4.4 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS
7 RADIOTHERAPY MARKET, BY APPLICATION (Page No. - 97)
7.1 INTRODUCTION
TABLE 28 RADIOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
7.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS
TABLE 29 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 30 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.2.1 PROSTATE CANCER
7.2.1.1 High incidence rate and efficiency of EBRT for prostate cancer treatment to drive the growth of this market segment
TABLE 31 EXTERNAL BEAM RADIOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
7.2.2 BREAST CANCER
7.2.2.1 Therapeutic benefits of EBRT for breast cancer over other treatments to drive the growth of this market segment
TABLE 32 EXTERNAL BEAM RADIOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
7.2.3 LUNG CANCER
7.2.3.1 Radiotherapy can be used as an adjuvant therapy with surgical procedures or chemotherapy or as a curative therapy for lung cancer
TABLE 33 EXTERNAL BEAM RADIOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
7.2.4 HEAD & NECK CANCER
7.2.4.1 Benefits of EBRT will increase its use in head and neck cancer treatment
TABLE 34 EXTERNAL BEAM RADIOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2019–2026 (USD MILLION)
7.2.5 COLORECTAL CANCER
7.2.5.1 Availability of alternative therapeutic options to limit the growth of this market segment
TABLE 35 EXTERNAL BEAM RADIOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
7.2.6 OTHER CANCERS
TABLE 36 EXTERNAL BEAM RADIOTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS
TABLE 37 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 38 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.3.1 PROSTATE CANCER
7.3.1.1 Precision and rapidity of brachytherapy in prostate cancer treatment to drive the growth of this market segment
TABLE 39 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
7.3.2 GYNECOLOGICAL CANCER
7.3.2.1 Availability of alternatives to hinder the adoption of brachytherapy in gynecological cancer treatment
TABLE 40 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2019–2026 (USD MILLION)
7.3.3 BREAST CANCER
7.3.3.1 Precision and rapidity of brachytherapy treatment are driving its use in breast cancer applications
TABLE 41 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
7.3.4 CERVICAL CANCER
7.3.4.1 Brachytherapy is an important part of the treatment of cervical cancer patients when radiation therapy is the primary choice of curative treatment
TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR CERVICAL CANCER, BY REGION, 2019–2026 (USD MILLION)
7.3.5 PENILE CANCER
7.3.5.1 Interstitial brachytherapy is the standard conservative therapy for localized penile cancer
TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PENILE CANCER, BY REGION, 2019–2026 (USD MILLION)
7.3.6 OTHER CANCERS
TABLE 44 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
8 RADIOTHERAPY MARKET, BY PROCEDURE (Page No. - 113)
8.1 INTRODUCTION
TABLE 45 RADIOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
8.2 EXTERNAL BEAM RADIOTHERAPY
TABLE 46 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 47 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.3 IMAGE-GUIDED RADIOTHERAPY
TABLE 48 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.3.1 INTENSITY-MODULATED RADIOTHERAPY
8.3.1.1 The radiation intensity of each beam in IMRT is controlled, and the beam shape changes throughout each treatment.
TABLE 49 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.3.2 3D CONFORMAL RADIOTHERAPY
8.3.2.1 Multiple beams with 3D-CRT allow precise radiation conforming to the tumor shape and size
TABLE 50 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.3.3 STEREOTACTIC THERAPY
8.3.3.1 Stereotactic therapy offers a minimally invasive alternative to ablation surgeries
TABLE 51 STEREOTACTIC THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.3.4 PARTICLE THERAPY
8.3.4.1 Adoption of particle therapy as the primary mode of cancer treatment is increasing
TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.4 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
TABLE 53 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 54 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.4.1 HIGH-DOSE-RATE BRACHYTHERAPY
8.4.1.1 Electronic brachytherapy is one of the recent advancements in this technique
TABLE 55 HIGH-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.4.2 LOW-DOSE-RATE BRACHYTHERAPY
8.4.2.1 Lower risk of radiation exposure to the surrounding tissues to support the growth of this market segment
TABLE 56 LOW-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.4.3 PULSED-DOSE-RATE BRACHYTHERAPY
8.4.3.1 Pulsed-dose-rate brachytherapy combines the advantages of HDR and LDR brachytherapy
TABLE 57 PULSED-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
8.5 SYSTEMIC RADIOTHERAPY
8.5.1 INTRAVENOUS RADIOTHERAPY
8.5.2 ORAL RADIOTHERAPY
8.5.3 INSTILLATION RADIOTHERAPY
9 RADIOTHERAPY MARKET, BY END USER (Page No. - 126)
9.1 INTRODUCTION
TABLE 58 RADIOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 HOSPITALS
9.2.1 INCREASING NUMBER OF SUPPLY DEALS OF ADVANCED RADIOTHERAPY PRODUCTS BETWEEN COMPANIES AND HOSPITALS TO DRIVE MARKET GROWTH
TABLE 59 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
9.3 INDEPENDENT RADIOTHERAPY CENTERS
9.3.1 RISING CONSOLIDATION OF HEALTHCARE NETWORKS IS CHALLENGING THE GROWTH OF FREE-STANDING RADIOTHERAPY CENTERS
TABLE 60 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2019–2026 (USD MILLION)
10 RADIOTHERAPY MARKET, BY REGION (Page No. - 130)
10.1 INTRODUCTION
TABLE 61 RADIOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 22 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT
TABLE 62 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 019–2026 (USD MILLION)
TABLE 72 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Changes in the reimbursement scenario to drive market growth in the US
TABLE 74 US: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 75 US: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 US: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 77 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing incidence of cancer to drive market growth in Canada
TABLE 78 CANADA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 79 CANADA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 CANADA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 82 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 83 EUROPE: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 84 EUROPE: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 85 EUROPE: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 86 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 EUROPE: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 90 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 92 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 93 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany is the largest market for radiotherapy in Europe
TABLE 94 GERMANY: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 95 GERMANY: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 GERMANY: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 High healthcare expenditure in France to drive market growth
TABLE 98 FRANCE: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 99 FRANCE: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 FRANCE: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.3 UK
10.3.3.1 Increasing prevalence of cancer to drive market growth in the UK
TABLE 102 UK: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 103 UK: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 UK: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.4 SPAIN
10.3.4.1 Increasing number of conferences and government funding for cancer research to drive market growth in Spain
TABLE 106 SPAIN: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 107 SPAIN: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 SPAIN: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Increasing awareness activities to support market growth
TABLE 110 ITALY: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 111 ITALY: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 ITALY: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 114 ROE: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 115 ROE: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 ROE: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 ROE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 23 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT
TABLE 118 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 119 ASIA PACIFIC: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 120 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 ASIA PACIFIC: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 122 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 ASIA PACIFIC: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 128 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 129 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Rising geriatric population and subsequent increase in the prevalence of cancer to drive market growth in Japan
TABLE 130 JAPAN: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 131 JAPAN: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 132 JAPAN: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 133 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Increasing number of strategic partnerships and supply deals to drive market growth
TABLE 134 CHINA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 135 CHINA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 CHINA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 High need for radiotherapy systems in the country is expected to offer growth opportunities to market players
TABLE 138 INDIA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 139 INDIA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 140 INDIA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.4 SOUTH KOREA
10.4.4.1 Increasing incidence of cancer to drive market growth in South Korea
TABLE 142 SOUTH KOREA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 143 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 144 SOUTH KOREA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 145 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Increasing prevalence of cancer to drive market growth in Australia
TABLE 146 AUSTRALIA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 147 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 AUSTRALIA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 150 ROAPAC: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 151 ROAPAC: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 152 ROAPAC: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ROAPAC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
TABLE 154 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 155 LATIN AMERICA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 156 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 157 LATIN AMERICA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 159 LATIN AMERICA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 162 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 164 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 165 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Increasing cancer incidence to drive market growth in Brazil
TABLE 166 BRAZIL: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 167 BRAZIL: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 168 BRAZIL: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 169 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Increasing awareness programs fueling market growth in Mexico
TABLE 170 MEXICO: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 171 MEXICO: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 MEXICO: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 174 ROLA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 175 ROLA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 ROLA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 ROLA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN THE MEA
TABLE 178 MEA: RADIOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 179 MEA: EXTERNAL BEAM RADIOTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 180 MEA: LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 181 MEA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 MEA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 MEA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 MEA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 MEA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 186 MEA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 187 MEA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 188 MEA: RADIOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 195)
11.1 OVERVIEW
FIGURE 24 KEY DEVELOPMENTS IN THE RADIOTHERAPY MARKET (JANUARY 2018 TO MAY 2021)
11.2 MARKET SHARE ANALYSIS
11.2.1 GLOBAL RADIOTHERAPY MARKET SHARE ANALYSIS (2020)
FIGURE 25 GLOBAL RADIOTHERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
11.3 COMPANY EVALUATION QUADRANT
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
FIGURE 26 RADIOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
FIGURE 27 RADIOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS (2020)
11.4 COMPETITIVE SCENARIO
11.4.1 PRODUCT LAUNCHES AND APPROVALS
TABLE 189 RADIOTHERAPY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2018 TO MAY 2021
11.4.2 EXPANSIONS
TABLE 190 RADIOTHERAPY MARKET: KEY EXPANSIONS, JANUARY 2018 TO MAY 2021
11.4.3 DEALS
TABLE 191 RADIOTHERAPY MARKET: KEY DEALS, JANUARY 2018 TO MAY 2021
12 COMPANY PROFILES (Page No. - 202)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM view)*
12.1.1 VARIAN MEDICAL SYSTEMS, INC.
TABLE 192 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 28 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
12.1.2 ELEKTA AB
TABLE 193 ELEKTA AB: BUSINESS OVERVIEW
FIGURE 29 ELEKTA AB: COMPANY SNAPSHOT
12.1.3 ACCURAY INCORPORATED
TABLE 194 ACCURAY INCORPORATED: BUSINESS OVERVIEW
FIGURE 30 ACCURAY INCORPORATED: COMPANY SNAPSHOT
12.1.4 BECTON, DICKINSON AND COMPANY
TABLE 195 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 31 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
12.1.5 IBA WORLDWIDE
TABLE 196 IBA WORLDWIDE: BUSINESS OVERVIEW
FIGURE 32 IBA WORLDWIDE: COMPANY SNAPSHOT
12.1.6 VIEWRAY, INC.
TABLE 197 VIEWRAY, INC.: BUSINESS OVERVIEW
FIGURE 33 VIEWRAY, INC.: COMPANY SNAPSHOT
12.1.7 ISORAY MEDICAL
TABLE 198 ISORAY MEDICAL: BUSINESS OVERVIEW
FIGURE 34 ISORAY MEDICAL, INC.: COMPANY SNAPSHOT
12.1.8 HITACHI LTD.
TABLE 199 HITACHI LTD.: BUSINESS OVERVIEW
FIGURE 35 HITACHI LTD.: COMPANY SNAPSHOT
12.1.9 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.
TABLE 200 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: BUSINESS OVERVIEW
12.1.10 PROVISION HEALTHCARE
TABLE 201 PROVISION HEALTHCARE: BUSINESS OVERVIEW
12.1.11 MEVION MEDICAL SYSTEMS
TABLE 202 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW
12.1.12 OPTIVUS PROTON THERAPY, INC.
TABLE 203 OPTIVUS PROTON THERAPY: BUSINESS OVERVIEW
12.1.13 P-CURE
TABLE 204 P-CURE: BUSINESS OVERVIEW
12.1.14 SUMITOMO HEAVY INDUSTRIES LTD.
TABLE 205 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 36 SUMITOMO HEAVY INDUSTRIES: COMPANY SNAPSHOT
TABLE 206 THERAGENICS CORPORATION: BUSINESS OVERVIEW
12.1.15 ZEISS GROUP
TABLE 207 ZEISS GROUP: BUSINESS OVERVIEW
FIGURE 37 ZEISS GROUP: COMPANY SNAPSHOT
12.2 OTHER PLAYERS
12.2.1 INTRAOP MEDICAL, INC.
12.2.2 ICAD, INC.
12.2.3 ECKERT & ZIEGLER
12.2.4 SENSUS HEALTHCARE
12.2.5 S.I.T SORDINA IORT TECHNOLOGIES S.P.A.
*Details on Business Overview, Products Offered, Recent Developments, MnM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 251)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the radiotherapy market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Primary research was conducted after acquiring extensive knowledge about the global radiotherapy market scenario through secondary research. Primary interviews were conducted with market experts from both the demand-side (such as CROs, hospitals, transplant centers, healthcare service providers, commercial service providers, academia, and research organizations) and supply-side respondents (such as presidents, CEOs, vice presidents, directors, general managers, heads of business units, and senior managers) across five major geographies, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa. Approximately 60% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 40%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochur
Market Estimation Methodology
A detailed market estimation approach was followed to estimate and validate the size of the global radiotherapy market and other dependent submarkets.
- The key players in the global radiotherapy market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights on the global radiotherapy market.
- All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.
- All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation:
After deriving the overall Radiotherapy market value data from the market size estimation process, the total market value data was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all the segments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various qualitative and quantitative variables as well as by analyzing regional trends for both the demand- and supply-side macro indicators.
Report Objectives:
- To define, describe, and forecast the radiotherapy market on the basis of product, procedure, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the radiotherapy market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Australia, South Korea, and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; business expansions and research & development activities in the radiotherapy market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global radiotherapy market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Europe radiotherapy market into Belgium, Austria, the Czech Republic, Denmark, Greece, Poland, and Russia, among other
- Further breakdown of the Rest of Asia Pacific radiotherapy market into New Zealand, Vietnam, the Philippines, Singapore, Malaysia, Thailand, and Indonesia among other
- Further breakdown of the Latin American radiotherapy market into Argentina, Chile, Peru, and Colombia, among other
Get in-depth analysis of the COVID-19 impact on the Radiotherapy Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Radiotherapy Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Radiotherapy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Radiotherapy Market